CARDIOVASCULAR JOURNAL OF AFRICA • Vol 22, No 3, May/June 2011
AFRICA
139
ed, HIV-1-infected South Africans. Attenuation of the protective
effect of HDL-C probably worsened the endothelial inflamma-
tion. Although no indication of a prothrombotic state, which
could result in atherosclerotic disease could be detected, there
was an indication of accelerated vascular aging and probable
early atherosclerosis in the older HIV-infected participants.
This work was financially supported by SANPAD (South Africa–
Netherlands Research Programme on Alternatives in Development), South
African National Research Foundation (NRF GUN numbers 2069139 and
FA2006040700010), North-West University, Population Health Research
Institute (PHRI), and the Medical Research Council (MRC) of South Africa.
We thank Prof A Kruger, the PURE-SA research team, the field work-
ers and office staff in the Africa Unit for Transdisciplinary Health Research
(AUTHeR), North-West University, South Africa, as well as Dr S Yusuf
(PURE-International) and the PURE project staff at the PHRI, Hamilton
Health Sciences and McMaster University, Ontario, Canada.
References
1.
Lee YW, Eum SY, Nath A, Toborek M. Estrogen-mediated protection
against HIV Tat protein-induced inflammatory pathways in human
vascular endothelial cells.
Cardiovasc Res
2004;
63
(1): 139–148.
2.
Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly
active antiretroviral therapy on leukocyte adhesion molecules, arterial
inflammation, dyslipidemia, and atherosclerosis.
Atherosclerosis
2006;
185
(1): 1–11.
3.
Constans J, Conri C. Circulating markers of endothelial function in
cardiovascular disease.
Clin Chim Acta
2006;
368
(1-2): 33–47.
4.
Hsue PY, Lo JC, Franklin A
et al
. Progression of atherosclerosis as
assessed by carotid intima-media thickness in patients with HIV infec-
tion.
Circulation
2004;
109
(13): 1603–1608.
5.
Glazier JJ, Spears JR, Murphy MC. Interventional approach to recur-
rent myocardial infarction in HIV-1 infection.
J Interv Cardiol
2006;
19
(1): 93–98.
6.
Sliwa K, Wilkinson D, Hansen C,
et al
. Spectrum of heart disease and
risk factors in a black urban population in South Africa (the Heart of
Soweto Study): a cohort study.
Lancet
2008;
371
(9616): 915–922.
7.
UNAIDS Sub-Saharan Africa. Aids epidemic update. Regional
Summary 2008. Accessed March 2009.
/
Report/2008/jc1526_epibriefs_ssafrica_en.pdf.
8.
Coll B, van Wijk JP, Parra S,
et al
. Effects of rosiglitazone and
metformin on postprandial paraoxonase-1 and monocyte chemoattract-
ant protein-1 in human immunodeficiency virus-infected patients with
lipodystrophy.
Eur J Pharmacol
2006;
544
(1–3): 104–110.
9.
Schillaci G, De Socio GV, Pucci G,
et al
. Aortic stiffness in untreat-
ed adult patients with human immunodeficiency virus infection.
Hypertension
2008;
52
(2): 308–313.
10. Andrade AC, Cotter BR. Endothelial function and cardiovascular
diseases in HIV infected patient.
Braz J Infect Dis
2006;
10
(2):
139–145.
11. De Larranaga GF, Bocassi AR, Puga LM,
et al
. Endothelial markers
and HIV infection in the era of highly active antiretroviral treatment.
Thromb Res
2003;
110
(2–3): 93–98.
12. Wu JT, Wu LL. Linking inflammation and atherogenesis: Soluble mark-
ers identified for the detection of risk factors and for early risk assess-
ment.
Clin Chim Acta
2006;
366
(1–2): 74–80.
13. Lorenz MW, Stephan C, Harmjanz A,
et al
. Both long-term HIV
infection and highly active antiretroviral therapy are independent risk
factors for early carotid atherosclerosis.
Atherosclerosis 2008;
196
(2):
720–726.
14. Jacobs GB, de Beer C, Fincham JE,
et al
. Serotyping and genotyping of
HIV-1 infection in residents of Khayelitsha, Cape Town, South Africa.
J
Med Virol
2006;
78
(12): 1529–1536.
15. Peeters M. The genetic variability of HIV-1 and its implications.
Transfus Clin Biol
200;
8
(3): 222–225.
16. Gaschen B, Taylor J, Yusim K,
et al
. Diversity considerations in HIV-1
vaccine selection.
Science
2002;
296
(5577): 2354–2360.
17. Freire E. Overcoming HIV-1 resistance to protease inhibitors.
Drug
Discovery
2006;
3
(2): 281–286.
18. Bessong PO, Larry OC, Cilliers T
et al
. Characterization of human
immunodeficiency virus type 1 from a previously unexplored region of
South Africa with a high HIV prevalence.
AIDS Res Hum Retroviruses
2005;
21
(1): 103–109.
19. Coll B, Parra S, Alonso-Villaverde C,
et al
. HIV-infected patients with
lipodystrophy have higher rates of carotid atherosclerosis: the role of
monocyte chemoattractant protein-1.
Cytokine
2006;
34
(1–2): 51–55.
20. de Gaetano DK, Rabagliati R, Iacoviello L, Cauda R. HIV infection,
HAART, and endothelial adhesion molecules: current perspectives.
Lancet Infect Dis
2004;
4
(4): 213–222.
21. Masia M, Bernal E, Padilla S,
et al
. The role of C-reactive protein as a
marker for cardiovascular risk associated with antiretroviral therapy in
HIV-infected patients.
Atherosclerosis
2007;
195
(1): 167–171.
22. Teo K, Chow CK, Vaz M,
et al
. The Prospective Urban Rural
Epidemiology (PURE) study: Examining the impact of societal influ-
ences on chronic noncommunicable diseases in low-, middle-, and
high-income countries.
Am Heart J
2009;
158
: 1–7.
23. World Medical Association Declaration of Helsinki. Ethical principles
for Medical Research Involving Human Subjects.
.
net/e/policy/b3.htm. Aaccessed February 2009.
24. ISAK – International Society for theAdvancement of Kinanthropometry
(ISAK). International standards for anthropometric assessment.
Adelaide: National Library of Australia; 2001: 133.
25. Gordon T, Castelli WP, Hjortland MC,
et al
. High density lipoprotein
as a protective factor against coronary heart disease. The Framingham
Study.
Am J Med
1977;
62
(5): 707–714.
26. Zhang Y, Zanotti I, Reilly MP,
et al
. Overexpression of apolipoprotein
A-I promotes reverse transport of cholesterol from macrophages to
feces
in vivo
.
Circulation
2003;
108
(6): 661–663.
27. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrom-
botic actions of HDL.
Circ Res
2006;
98
(11): 1352–1364.
28. Barter PJ, Nicholls S, Rye KA,
et al
. Anti-inflammatory properties of
HDL.
Circ Res
2004;
95
(8): 764–772.
29. Negre-Salvayre A, Dousset N, Ferretti G,
et al
. Antioxidant and cyto-
protective properties of high-density lipoproteins in vascular cells.
Free
Radic Biol Med
2006;
41
(7): 1031–1040.
30. Patel S, Puranik R, Nakhla S,
et al
. Acute hypertriglyceridaemia in
humans increases the triglyceride content and decreases the anti-
inflammatory capacity of high density lipoproteins.
Atherosclerosis
2009;
204
(2): 424–428.
31. Wadham C, Albanese N, Roberts J,
et al
. High-density lipoproteins
neutralize C-reactive protein proinflammatory activity.
Circulation
2004;
109
(17): 2116–2122.
32. De Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum
marker of cardiovascular risk.
Cardiovasc Pathol
2007;
16
(1): 14–21.
33. O’Brien KD, McDonald TO, Chait A,
et al
. Neovascular expression of
E-selectin, intercellular adhesion molecule-1, and vascular cell adhe-
sion molecule-1 in human atherosclerosis and their relation to intimal
leukocyte content.
Circulation
1996;
93
(4): 672–682.
34. Ross R. Atherosclerosis – an inflammatory disease.
N Engl J Med
1999;
340
(2): 115–26.
35. Dhawan S, Puri RK, Kumar A,
et al
. Human immunodeficiency
virus-1-tat protein induces the cell surface expression of endothelial
leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and
intercellular adhesion molecule-1 in human endothelial cells.
Blood
1997;
90
(4): 1535–1544.
36. Liu K, Chi DS, Li C,
et al
. HIV-1 Tat protein-induced VCAM-1 expres-
sion in human pulmonary artery endothelial cells and its signaling.
Am
J Physiol Lung Cell Mol Physiol
2005;
289
(2): L252–L260.
37. Cohn JN. Arterial compliance to stratify cardiovascular risk: more
precision in therapeutic decision making.
Am J Hypertens
2001;
14
(8
Pt 2): 258S–263S.
38. Alpert BS, Collins RT. Assessment of vascular function: pulse wave
velocity.
J Pediatr
2007;
150
(3): 219–220.
39. vanWijk JP, de Koning EJ, Cabezas MC,
et al
. Functional and structural
markers of atherosclerosis in human immunodeficiency virus-infected
